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Many countries hit by the COVID-19 epidemic consider the introduction of vaccina-23
tion passes. So far, no thorough impact assessment of vaccination passes and of lower24
restrictions for their holders has been conducted. Here, we propose the VAP-SIRS model25
that accounts for susceptible, infected, and recovered subpopulations, also within the26
group of vaccinated pass holders. The model accounts for imperfect vaccination effec-27
tiveness, revaccinations and waning immunity. Different restrictions for pass holders and28
the rest of the population result in different scenarios of the epidemic evolution, some of29
which yield unfavourable COVID-19 dynamics and new waves. We identify critical vari-30
ables that should be considered by policymakers and show how unfavourable outcomes31
can be avoided using adaptive policies. In particular, while pass holders could initially be32
allowed large freedoms, the gradual loss of immunity will require either increased restric-33
tions for pass holders, or accelerated revaccination. In the long-term, common restrictions34
for both the pass holders and the rest of the population will have to be kept to avoid epi-35
demic resurgence. Such minimum required restrictions depend on vaccination effective-36
ness, revaccination rate, waning rate and fraction of never-vaccinated population, and,37
for realistic combinations of these parameters, range between 29% and 69% reduction of38
contacts.39
Main40
In the past, governments have required proof of vaccination for travel, with yellow fever being41
the best-known example, and the only disease for which a certificate is needed to cross borders42
in compliance to the International Health Regulations1. However, the idea that proof of vac-43
cination will become a prerequisite for crossing borders or to enter facilities, visit businesses44
premises, participate in events, and generally enjoy more freedom, has only arisen in the context45
of combatting the COVID-19 epidemic. Despite technical challenges, scientific uncertainties,46
and ethical and legal dilemmas, the idea of vaccination passes (VPs), i.e., documents issued on47
the basis of vaccination status, is now receiving unprecedented attention2,3,4. Many consider48
VPs as tools to restore people’s freedoms and increase well-being, whilst allowing economies49
to reopen. Determining immunity status is challenging, as the immune response and its dura-50
2
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256847doi: medRxiv preprint 
tion may greatly vary; this being applicable to post-vaccination immunity, as well as following51
natural SARS-CoV-2 infection and recovery5. It is, therefore, critically important to determine52
levels of restrictions that offer safety whilst being tolerable, ensuring good compliance and53
rational behaviour. Less than perfect conferred protection coupled with suboptimal levels of54
restrictions can have detrimental effects. The lack of a comprehensive framework to determine55
such levels, including when approaching higher vaccination coverage and even herd immunity,56
may result in policymakers opting to select suboptimal levels of restrictions. This may happen57
for different reasons, such as lack of true understanding of the ramifications, to boost morale or,58
even, for political gain. Evidence indicates vaccine effectiveness can greatly vary6,7 and it may59
be compromised due to escape variants8 and waning immunity9,10,11,12.60
Various models have been developed to inform vaccination strategies13,14,15,16,17,18,19,20,21.61
One such effort indicates lower vaccine effectiveness coupled with an increase in social con-62
tact among those vaccinated (behavioral compensation) may undermine vaccination effects,63
even without considering immunity waning22. So far, there has been no model to focus on the64
medium- and long-term impact of relaxing restrictions for VP holders, with due consideration to65
vaccine effectiveness, durability of response, and vaccine hesitancy. The proposed VAP-SIRS66
model delivers a systematic framework to assess key considerations for policymaking.67
Results68
The VAP-SIRS model of the impact of COVID-19 vaccination passes69
The VAP-SIRS model extends the classical SIRS model23 (red arrows in Fig. 1a) with addi-70
tional states and parameters that describe the dynamics of vaccination routine in a population71
(green arrows in Fig 1a.). To this end, we consider the following subpopulations: (i) initially72
susceptible SN , who, if successfully vaccinated, populate the immune group V , with rate aυ,73
where υ is the vaccination rate and a is the effectiveness, (ii) susceptible who were vaccinated74
but did not gain immunity (S1), (iii) vaccinated, whose immunity waned with rate ω and be-75
came susceptible again (S2), (iv) susceptible, who are not and will never get vaccinated (SD).76
Additionally, revaccination of S2 populates V with rate aυr. All recovered, unless recovered77
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compartment RD, are also subject to vaccination. The fraction of the population that will never78
be vaccinated is denoted d.79
The presented model analysis is performed for carefully selected parameter setups: two80
different vaccination rates, 0.004 and 0.008 dose per person daily, chosen on the basis of the81
current rates observed in Europe24,25, and for vaccine effectivenesses 0.6 and 0.9, which conser-82
vatively model that of the most widely used vaccines: Vaxzevria (AstraZeneca)26,27 and Comir-83
naty (BioNTech/Pfizer)28,7,29, respectively. Furthermore, optimistic (500 days; ω = 1/500)84
and pessimistic (200 days; ω = 1/200) average immunity duration periods are considered, re-85
flecting emerging data on large individual variation of immunity waning and other key factors86
influencing this process9,12,30,31,32. Finally, across the manuscript, we assume the revaccination87
rate υr = υ, and consider optimistic 0.1, and pessimistic 0.3 fractions of never-vaccinated d .88
We assume that VP holders are all who were vaccinated at least once (Fig. 1). The restriction89
level f (ranging from 0 to 1) is introduced as a modulator of the SARS-CoV-2 reproduction90
number. Here, we consider that without any restrictions (f = 0), the reproduction number for91
the virus equals 4, as an optimistic estimate for B.1.1.733,34. Similarly, restrictions fv ≤ f for92
contacts among VP holders are considered. f and fv should be interpreted as the net effect93
of all factors that reduce the reproduction number of the virus within the respective groups:94
all applied non-pharmaceutical interventions together with the resulting changes in behavior.95
Based on the current studies, we fix the generation time to 6 days (γ = 1/6)34,33. Finally, we96
consider two types of mixing between subpopulations: proportional (typical for SIR models)97
and preferential, where the VP holders prefer contacts with other VP holders. See Methods for98
a detailed model description.99
VAP-SIRS predicts a possible infection resurgence despite vaccinations100
VAP-SIRS predicts unfavourable epidemic dynamics for a wide range of parameters. As an101
example consider: a = 0.9, υ = υr = 0.004, d = 0.1, and ω = 1/500, a seemingly safe102
setup, which we will call the reference setup. For such setup and low restrictions fv = 0.05103
for VP holders as well as medium restrictions f = 0.63 for contacts with and within the rest104
of the population, the model predicts a small wave of infections shortly after the vaccination105
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program starts, followed by a large wave later (Fig. 1b). This behavior is explained by the106
population structure and different restrictions (Fig. 1c). In this scenario, the first wave is driven107
by the unvaccinated susceptibles (SN ) and suppressed by ongoing vaccination, as expected.108
Interestingly, the second, larger wave is driven by the SV group. The SV group is composed of109
the number of individuals for whom the vaccine was ineffective (S1) and those vaccinated who110
lose their immunity and are not yet revaccinated (S2). In the following we investigate how the111
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Figure 1: The VAP-SIRS model shows the possible rebound of infections after a large
population is vaccinated and obtains a VP, but then loses immunity. a. Graphical scheme
of the VAP-SIRS model. b. The timeline of daily incidence per 1 million inhabitants for an
effective vaccine (a = 0.9), slow (re-)vaccination rate (υ = υr = 0.004; typical for many
European countries), proportional mixing (see Methods) and low fraction of never-vaccinated
(d = 0.1). Here, a variable with the asterisk (∗) indicates that we consider a daily incidence over
the corresponding variable, thus I∗ stands for I∗D + I
∗
N , and by I
∗
Σ we mean the sum of all daily
infected (I∗ + I∗1 + I
∗
2 ). c. The Muller plot of the population structure (the width of the color
band in the y axis) as a function of time (x axis) for the same parameter settings as in b. Here,
by IΣ and RΣ we denote I + IV and R +RV , respectively.
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Stability analysis identifies potential scenarios for the COVID-19 epidemic113
depending on the restrictions imposed on VP holders and the rest of the114
population.115
To assess the epidemic evolution in different scenarios, we analysed stability by linearising the116
model equations with I = R = 0 (Methods). The restriction levels f = (f, fv) influence117
the instantaneous reproduction number R∗. R∗(t) is the reproduction number that would be118
observed at time t, given the restrictions f and the composition of the population, where the119
number of infected is very small. If R∗(t) > 1, then switching to f at time t results in an120
overcritical epidemic evolution, with an initially exponential growth of infections; ifR∗(t) < 1,121
switching to f at time t results in a subcritical epidemic evolution, where the number of active122
cases decreases to zero. The R∗ is more informative of epidemic thresholds than the standard123
effective reproduction number, as it does not depend on the actual number of infected and124
recovered.125
We consider five restriction choices (prototypical for five regions of the parameter space),126
leading to different time profiles of R∗ (Fig. 2a). Medium restrictions for both VP holders127
and the rest of the population (red curve in Fig. 2a) lead to an overcritical epidemic. Medium128
restrictions for VP holders and strong restrictions for the others (blue curve in Fig. 2a) lead to129
a subcritical epidemic. With low restrictions for VP holders and medium restrictions for the130
rest of the population (orange curve in Fig. 2a), the epidemic is initially overcritical, becomes131
subcritical and then switches to overcritical again; this is the scenario shown in the simulation132
in Fig. 1b,c. With very low restrictions for VP holders and strong restrictions for the rest of133
the population (pink curve in Fig. 2a), the epidemic is initially subcritical and then becomes134
overcritical. If low restrictions are adopted for VP holders and medium restrictions for the rest135
of the population (cyan curve in Fig. 2a), the epidemic is initially overcritical and then switches136
to subcritical.137
In each scenario we computed the time evolution of the instantaneous doubling time D138
(Methods). For a given f , D(t) is the doubling time (capturing how fast the infections grow)139
that would be observed for the growth of a small initial number of infections at time t, with140
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enforced restrictions f . Very short doubling times, below 30 days, can be observed in three141
scenarios that are (eventually) overcritical: see the red, orange and pink curves in Fig. 2b.142



















Figure 2: Intensity and timing of the infection wave: examples of five scenarios depending
on the restrictions for VP holders and for the rest of the population. Given a = 0.9,
υ = υr = 0.004, ω = 0.002, d = 0.1 and proportional mixing, we compare five different
scenarios describing the epidemic evolution: overcritical (+, red, f = 0.45 and fv = 0.32),
subcritical (-, blue, f = 0.82 and fv = 0.4), initially and eventually overcritical (+-+, orange,
f = 0.63 and fv = 0.05), eventually overcritical (-+, pink, f = 0.92 and fv = 0.04), eventually
subcritical (+-, cyan, with f = 0.7 and fv = 0.4). a. Time evolution of R∗ (y axis) depending
on the number of days counted from the start of the vaccination program (x axis). b. Doubling
time D (y axis, in days) as a function of the number of days (x axis). Note that doubling
curves are cut above 100 days, in the time intervals indicated by the horizontal dashed lines.
Negative doubling times (halving times) are not plotted. Thus, the subcritical scenario (-) is
not visualised in b. Vertical dotted lines indicate the times at which a transition occurs from
overcritical to subcritical, or vice versa.
Different restrictions are required to avoid epidemic resurgence depending143
on parameter setups144
The relevant f − fv parameter space, where fv ≤ f , can be divided into five regions, where the145
epidemic dynamics follows the distinct patterns exemplified in Figure 2. The area occupied by146
each region changes depending on the parameter setups, as shown in Figure 3. For example,147
in the reference setup in Figure 3a (high vaccine effectiveness a = 0.9 and (re-)vaccination148
rates υ = υr = 0.004, low never-vaccinated fraction d = 0.1 and low immunity waning rate149
ω = 0.002), the overcritical region (with R∗ always above 1) occupies the lower left corner. It150
is enlarged with smaller vaccine effectiveness (a = 0.6, Fig. 3b), larger fraction of the never-151
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vaccinated population (Fig. 3e) and higher waning rate (Fig. 3f), while it shrinks with higher152
vaccination rate (Fig. 3c). The subcritical region - (with R∗ always smaller than 1) lies in153
the opposite corner of the f − fv space, for larger values, and for a fixed fraction of never-154
vaccinated d tends to decrease for setups where the overcritical region increases. Inside each of155
the remaining three regions (associated with the +-+, -+, +- scenarios in Figure 2), the specific156
parameter settings differ by the time to the critical threshold of interest for that region (the last157
observed switch between subcritical and overcritical epidemic, which for the +-+ region, for158
example, is the second critical threshold; see Methods for the computation of the times to critical159
thresholds). For the reference setup (Fig. 3a), the critical threshold is reached after a minimum160
∼ 8 months. Decreasing vaccine effectiveness (Fig. 3b), as well as increasing the waning rate161
(Fig. 3f), enlarges the +-+ region’ and leads to overcriticality sooner, after ∼ 3 and ∼ 4 months162
respectively, for low fv values. Increasing vaccination rate (Fig. 3c) shrinks the +-+ region.163
With preferential mixing (Fig. 3d), the +-+ region becomes larger and overcriticality is reached164
even sooner. Increasing the number of never-vaccinated people (Fig. 3e) shrinks the +-+ region165
and delays the onset of overcriticality. For all considered parameter setups, except for the one166
with high (re-)vaccination rate, for all except the +- and the - regions, large asymptotic R∗ can167
be expected, which corresponds to short doubling times (Fig. 3).168
These results indicate that VP holders can be granted large freedom, as long as sufficient169
restrictions are enforced for the rest of the population, to avoid an initially overcritical situation.170
However, to prevent the epidemic from becoming overcritical after an initial decline in case171
numbers, restrictions on VP holders need to be timely increased and adapted so that eventually172
everyone faces the same restrictions. Safe restrictions correspond to the parameters in the sub-173
critical region, but these are relatively high and could be unacceptable for the population. The174
-+ and +-+ regions can seem attractive from the aspect of large freedom for the VP holders.175
Both these regions, however, eventually result in epidemic resurgence and should be avoided.176
Moving to the +- region with the right timing is a recommendable strategy.177
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Figure 3: Possible COVID-19 epidemic dynamics depending on vaccine effectiveness, vac-
cination rate, mixing type and the restrictions for VP holders and for the rest of the pop-
ulation. For various choices of the other parameters, the relevant f − fv parameter space,
where fv ≤ f , can be divided into five regions, each associated with a different behavior of
the epidemic, exemplified by the five scenarios in Figure 2a. On the diagonal (white dashed
line), f = fv, namely the restrictions for VP holders and for the rest of the population are the
same. Lower triangles show the time until the last critical threshold: different colour scales cor-
respond to the time until the switch either from a subcritical to an overcritical epidemic (time
until overcriticality, violet-green scale), or from an overcritical to a subcritical epidemic (time
until subcriticality, yellow-pink scale). Upper triangles show the asymptotic R∗, as a function
of the values of f and fv (blue-red scale, with blue associated with R∗ < 1 and red associated
with R∗ > 1). a. Reference setup, with a = 0.9, υ = υr = 0.004, ω = 0.002, d = 0.1 and
proportional mixing. The choices of (f, fv) corresponding to the five scenarios exemplified in
Figure 2 are denoted by crosses of the same colour. b. Setup with decreased vaccine effec-
tiveness: a = 0.6. c. Setup with increased vaccination rate: υ = υr = 0.008. d. Setup with
preferential (instead of proportional) mixing. e. Setup with increased fraction of people who
will not get vaccinated: d = 0.3. f. Setup with increased waning rate: ω = 0.005.
9
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A minimum common restriction level is required to keep the epidemic sub-178
critical179
We compute the minimum common restriction level fmin for the whole population that would180
be required to avoid an overcritical epidemic in the long-term (Methods):181
fmin = max(0, 1− 1/(4 · (1− V as)),
where V as is the asymptotic fraction of the immunized in the population182
V as = (1− d) a
1 + ω/υr
.
The resulting values differ depending on the setups of vaccine effectiveness a, revaccination183
rate υr, the fraction of never-vaccinated population d and immunity waning rate ω (Tab. 1).184
Even for the most optimistic setup (high a = 0.9, high υr = 0.008, low d = 0.1, low ω =185
0.002) we obtain V as = 0.65, and fmin = 0.29. Compared to the current strict restrictions186
required to contain COVID-19 in some countries, the level of 0.29 restrictions is lower, but it is187
a considerable reduction of freedom compared to before the pandemic. All remaining realistic188
parameter setups require high fmin, ranging between 0.46 (for the reference setup) and 0.68 (for189
the increased d, increased ω as compared to the reference).190
Discussion191
Introducing VPs is widely seen as a means to opening up economies and societies, despite the192
ongoing epidemic. To inform this discussion, we extend a SIR model to reflect vaccination193
dynamics and possibly different restrictions for VP holders. A wide range of model parameter194
choices show the possibility of an epidemic resurgence, even for optimistic parameter setups.195
The main driver of this phenomenon is the potential lack of immunity of VP holders. With a196
VP, people enjoy low restrictions while actually being susceptible and potentially contagious197
because the vaccine was ineffective or the immunity has waned.198
VAP-SIRS deliberately keeps several aspects simple (see Methods for model limitations).199
10
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Parameter setup a υr d ω V as fmin
1 Reference setup (ref Fig. 3a) 0.9 0.004 0.1 0.002 0.54 0.46
2 Decreased a (ref Fig. 3b) 0.6 0.004 0.1 0.002 0.36 0.61
3 Increased υr (ref Fig. 3c) 0.9 0.008 0.1 0.002 0.65 0.29
4 Increased d (ref Fig. 3e) 0.9 0.004 0.3 0.002 0.42 0.57
5 Increased ω (ref Fig. 3f) 0.9 0.004 0.1 0.005 0.36 0.61
6 Decreased a and increased υr 0.6 0.008 0.1 0.002 0.43 0.56
7 Decreased a and increased d 0.6 0.004 0.3 0.002 0.28 0.65
8 Decreased a and increased ω 0.6 0.004 0.1 0.005 0.24 0.67
9 Increased υr, increased d 0.9 0.008 0.3 0.002 0.50 0.50
10 Increased υr, increased ω 0.9 0.008 0.1 0.005 0.50 0.50
11 Increased d, increased ω 0.9 0.004 0.3 0.005 0.21 0.68
Table 1: Asymptotic level of immunization V as and minimum common restrictions fmin
for different parameter setups, for parameters: vaccine effectiveness a, revaccination rate
υr, fraction of never-vaccinated d, and waning immunity rate ω. The first row concerns the
reference setup; rows below are setups with the same parameters as in the reference setup,
but with either one parameter changed (in bold; rows 2–5; same as in Figure 3, apart from
preferential mixing, as it is not relevant for common restrictions) or two parameters changed (in
bold; rows 6–11).
The advantage of our analysis is the relevance for long-term dynamics, and the focus on avoid-200
ing epidemic resurgence. Avoiding another wave is a prudent goal due to threats it poses, in the201
form of long-term health effects, the deleterious impact on societies and the emergence of new202
variants.203
Our model gives valuable insights into policies pertaining to the introduction of VPs. Model204
analyses suggest that considerably lowering restrictions for VP holders is only possible when205
keeping high restrictions on the rest of the population. This situation seems tolerable for the un-206
vaccinated only given high vaccine availability and vaccination speed. The alternative cautious207
option, i.e. not granting freedoms for VP holders, defeats the purpose of the instrument. Once208
a large part of the population has been vaccinated, policymakers need to find a new, common209
restriction level, which could also be achieved through temporary VPs. Our model implies that210
such common restrictions need to be higher than those initially granted to VP holders, and need211
to be introduced in time to avoid another wave.212
As expected, the model shows that there is a larger selection of admissible restrictions’213
setups under high vaccine effectiveness, slowly waning immunity, proportional social mixing,214
low share of never-vaccinated and higher vaccination rate. At least the latter two parameters215
are amenable to policy action. Thus, efforts to increase (re-) vaccination speed and encour-216
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age people to get vaccinated also extend the margin of lowering restrictions for VP holders as217
well as eventual common restrictions. Social mixing patterns, such as preferential mixing, can218
accelerate the infection resurgence in time and, although difficult to change by policymaking,219
should be monitored. Finally, it is noteworthy that VP holders are less likely to be tested, as they220
are assumed to be protected and they may exhibit milder symptoms. Therefore, their potential221
infection is more likely to remain undetected, resulting in an effect similar to that of lowering222
restrictions. To prevent undesirable outcomes, the testing criteria should not exclude the VP223
holders. In addition, the VP holders should be widely and regularly tested for antibody level,224
aiming at detection of such vaccinated that have lost, or have never gained, immunity. Finally,225
temporary VPs could be considered, with their prolongation conditioned on high antibody level226
or recent (re-)vaccination.227
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Methods1
Mathematical model2
We introduce a modified susceptible-infectious-recovered-susceptible (SIRS) model [1] (Figure3
1a). The population is divided into two subpopulations: those who are not vaccinated (S, I , R)4
and those who got vaccinated at least once (SV , IV , RV , V ). We assume that the group of5
non-vaccinated susceptible individuals S (and, similarly, infected I and recovered R) is divided6
into two subgroups: SN and SD. The SN compartment contains such susceptible who will7
eventually be vaccinated, while those in SD will not. The SD compartment contains not only8
the subpopulation of children, who are currently not included in the vaccination program, but9
also those who for health reasons cannot be vaccinated, and finally, individuals who do not10
vaccinate because of hesitancy.11
The SN population is vaccinated with rate υ and effectiveness a. Consequently, the individuals12
from the SN group populate the vaccinated group V with rate aυ. The individuals in V are13
considered immune, and we assume that immunization prevents them both from getting infected14
and infecting others. The SV compartment is composed of S1 and S2 (and, similarly, vaccinated15
infected IV consists of I1 and I2). Due to vaccine ineffectiveness, people in S1 are perceived16
as immunized, but in fact are susceptible. S1 is populated from SN with rate (1 − a)υ. The17
vaccinated from the V group move to the S2 group of susceptibles with immunity waning rate18
ω. The individuals from the S1 group move to S2 with the same rate ω. The S2 group is the19
group of vaccinated, but no longer immune, and thus, susceptible individuals. In contrast to20
S1, we consider that the S2 group is subject to revaccination. Consequently, a fraction of size21
a of the population from S2 populates V with rate aυr and a fraction of size (1 − a) populates22
S1 with rate (1 − a)υr. Across the manuscript, we assume υr = υ, but the model is general23
and different values can be considered. Individuals from S1 move to S2 with rate ω to ensure24
that the ineffectively vaccinated are revaccinated with the same speed as the ones for which the25
vaccine was effective.26
Some of the susceptibles in S1 (or, similarly, S2) may not get revaccinated fast enough and27
may become infected and populate I1 (or, I2). Then, as in the classical SIRS model, the I1 (or28
1
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I2) population recovers and populates group RV with rate γ. We consider that the recovered in29
RV may also lose the immunity, and become susceptible again and move to S2 with rate κ. We30
fix κ to 0.002, corresponding to average 500 days duration of natural immunity. There remains31
uncertainty regarding the waning time for natural immunity, but early evidence indicates it lasts32
at least 180 days [2, 3, 4]. Hence, we assume an optimistic scenario of natural immunity lasting33
similarly long as the immunity gained via vaccination. Before the recovered in the RV lose34
immunity, they might be revaccinated, and, thus, populate the V group with rate υr.35
The remaining susceptible subgroups (the SN and SD) may undergo the same classical36
dynamics, i.e., become infected, recover, and either become susceptible again or, in case of37
the recovered in the RN subgroup, become vaccinated with rate υ.38
Note that for the recovered in theRV orRN groups we assume that vaccination effectiveness39
is 1, which is substantiated on the basis of the fact that vaccination combined with a previous40
infection should confer a much stronger protection than only vaccination of a susceptible individual.41
The following parameters are used to describe population dynamics in the model:42
fv, f : restrictions level (for VP holders and others)
β0 : basic transmission rate
βv, β : transmission rate (for VP holders and others)
γ : recovery rate
κ : natural immunity waning rate
a : vaccination effectiveness
υ : vaccination rate
υr : revaccination rate
ω : vaccine-induced immunity waning rate
d : fraction of population that will never get vaccinated
Finally, the following set of ordinary differential equations (ODEs) defines the dynamics43
2
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d
dt
SD = − (βI + βIV )SD + κRD,
d
dt
SN = − (βI + βIV )SN − υSN + κRN ,
d
dt
S1 = υr (1− a)S2 + υ (1− a)SN − ωS1 − (βI + βvIV )S1,
d
dt
S2 = −υrS2 + ωV + ωS1 − (βI + βvIV )S2 + κRV ,
d
dt
V = υaSN + υraS2 − ωV + υrRV + υRN , (1)
d
dt
ID = (βI + βIV )SD − γID,
d
dt
IN = (βI + βIV )SN − γIN ,
d
dt
I1 = (βI + βvIV )S1 − γI1,
d
dt
I2 = (βI + βvIV )S2 − γI2,
d
dt
RV = γIV − κRV − υrRV ,
d
dt
RD = γID − κRD,
d
dt
RN = γIN − κRN − υRN ,
where also the following relations hold44
SV = S1 + S2,
IV = I1 + I2,
S = SD + SN ,
I = ID + IN ,
R = RN +RD,
with the constraint S, SV , I, IV , R,RV ≥ 0. Finally, to consider the subpopulation dynamics in45
terms of fractions of the entire subpopulation, we set46
S + SV + I + IV +R +RV = 1 (2)
3
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256847doi: medRxiv preprint 
and denote d to be the fraction of the never-vaccinated population
d = SD + ID +RD.
Modeling restrictions47
We assume that the VP holders consist of the following subpopulations of vaccinated at least48
once: V, SV , IV , RV . Recall that the net effect of all non-pharmaceutical interventions is modeled49
using parameters fv and f , called restrictions throughout the text. The parameter fv amounts to50
the level of restriction of contacts, and thus the ability to infect, within the group of VP holders.51
The parameter f satisfies f ≥ fv and corresponds to restriction of contacts within the rest of52
the population, as well as between the VP holders and the rest of the population.53
The restriction level fv for the VP holders is introduced in the model as a modulator of the54
transmission rate βv. Specifically, we assume that βv = β0(1−fv), where β0 is the transmission55
rate of the SARS-CoV-2 virus without restrictions. We assume fv ranges from 0 to 1, where56
fv = 0 corresponds to no restrictions enforced on the VP holders, and fv = 1 corresponding to57
full restrictions. Given that for fv = 0 the reproduction number Rmax = β0/γ = 4, and that the58
recovery rate γ = 1/6, we obtain the no-restriction transmission rate β0 = 2/3.59
Similarly, the transmission rate parameter β = β0(1 − f) describes the transmission rate60
within the rest of the population and between VP holders and the rest, given the restrictions f .61
Proportional versus preferential types of social mixing62
The above described model equations are based on the assumption that the social mixing63
between social groups in the population is proportional to the group sizes (the mass action64
principle). Instead, preferential mixing can be assumed, where the VP holders are more likely65
to contact other VP holders, since they have lower restrictions [5]. This preferential bias is66
proportional to the difference between the restrictions f and fv. To incorporate the preferential67
mixing effect in the ODE model (Equation 1) we rescale the interaction terms according to the68
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β(S + I +R) + βv (1− (S + I +R))
SIV
where S + I +R is the non-immune population.70
Model simulations71
For simulations, we solve the model numerically by means of joint Adams’ and BDF methods,72
as implemented in the R package deSolve, lsoda method of the ode function [6]. The method73
monitors data in order to select between non-stiff (Adams’) and stiff (BDF) methods. It uses74
the non-stiff method initially [7].75
To generate the data presented in Figure 1b,c, we use the reference setup of parameters:76
β0 = 2/3, f = 0.63 (and thus β = 0.247), fv = 0.05 (and thus βv = 0.634), γ = 1/6,77
κ = 1/500, a = 0.9, υ = υr = 1/250, ω = 1/500, d = 0.1, with initial conditions I = 10−6,78
ID = d · I = 10−7; IN = (1 − d) · I = 0.9 · 10−6, R = 0, V = 0. Given I(t) resulting79
from the solution of the model’s ODE system, to present the final results as easier interpretable80
cases per milion rather than fractions, we re-scale the results by 1M. Additionally, we compute81



















+ e−γI (t− 1) .








 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted May 14, 2021. ; https://doi.org/10.1101/2021.05.07.21256847doi: medRxiv preprint 
We proceed similarly to obtain daily incidence numbers I∗1 , I
∗
2 and for the sum of all infected,85
and again to make it interpretable in the figures we re-scale it by 1M.86
Stability analysis87
The vaccination dynamics can be solved explicitly in the absence of infections. Fixing I =88
IV = R = RV = 0, and assuming υ = υr, we obtain89
S(t) = d+ (1− d) e−υt,






SV (t) = 1− S − V.
For convenience, where it is not needed, we drop the time argument.90
Taking an adiabatic approach we linearize the infection dynamics for small I , IV and R
under the assumption of slowly varying S, SV and V . In that case, the infection dynamics
decouples from the vaccination dynamics and the Jacobian submatrix Jsub for the equations for
I and IV is given by:
Jsub =
βS − γ βS
βSV βV SV − γ
 .
Given the Jacobian submatrix, we can approximate the dynamics in a small neighborhood of91





βS − γ βS





The instantaneous reproduction number R∗ and the instantaneous doubling time D93
Since the largest and the second largest eigenvalues λmax and λ2 of Jsub are both real, the94
solution to Equation 3 providing the dynamics of infection numbers of the vaccinated and the95
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rest of the population in time can be written in the following form96
 I(t)
IV (t)
 = c1w1eλmaxt + c2w2eλ2t = eλmaxt(c1w1 + c2w2e(λ2−λmax)t), (4)
where w1 and w2 are the respective eigenvectors, and c1 and c2 are constants depending on the97
initial conditions.98
Since we have λ2 − λmax ≤ 0, we can approximate the time evolution of infection numbers99
by100  I(t)
IV (t)
 ≈ c1w1eλmaxt. (5)










S2β2 + S2V β
2
v − 2SSV ββv + 4SSV β2, (6)
whereby it is convenient to express λmax as a function of R1 = βγ and R2 =
βv
γ









(R1S −R2SV )2 + 4SSVR21 − 1
)
. (7)
Given the population fractions S(t) and SV (t) at a given time instant t, the linearized103
dynamics of infections given by Equation 3 has a corresponding two-type Galton-Watson branching104
process, which is a microscopic description of the dynamics. The two types of the process105
correspond to the I and IV groups. The type I individuals generate Pois (R1S) offsprings of106
type I and Pois (R1SV ) offsprings of type IV . The type IV individuals generate Pois (R1S)107
offsprings of type I and Pois (R2SV ) offsprings of type IV . The linearized dynamics (3) can108
then be understood as a mean field limit of the microdynamics described by such a branching109








4R21SSV + (R1S −R2SV )
2 (8)
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of the transition matrix R1S R1SV
R1S R2SV

of the branching process can be interpreted as the reproduction number of the branching process,111
since the expected number of infected in generation n grows like const · (R∗)n [8]. We refer to112
R∗ as the instantaneous reproduction number. The term instantaneous comes from the fact that113
we are considering the linearized adiabatic dynamics in a small neighborhood of the I = IV = 0114
(ref Eq. 3).115
The above discrete branching process can be extended to a continuous time branching
process by assuming a probability distribution on the generation time, denoted ϕ(γ). The
growth of the continuous time branching process const · eαt is characterized by its Malthusian
growth parameter, denoted α. The relation between the instantaneous reproduction number R∗,
the distribution ϕ (τ) and the Malthusian parameter α for such a branching process is given by
R∗ · Lϕ (α) = 1
whereLϕ (α) is the Laplace transform
∞∫
0
e−ατϕ (τ) dτ of the distribution ϕ [8]. Since the setting116
of ODE model (1) implies exponential distribution of the generation time, i.e, ϕ(γ) = Exp (γ),117
the following relation holds: α = γ (R∗ − 1) .118
By Equation 5, the Malthusian parameter α for our dynamics is given by the largest eigenvalue119
λmax. Hence we obtain the relation between the instantaneous reproduction R∗ and the λmax as120
λmax = γ (R
∗ − 1) . Note that since both S and SV are functions of time, so are λmax and R∗.121
It is noteworthy that in the above equations, all R1, R2, R1S and R2SV , and R∗ should be122
seen as reproduction numbers, but of a different nature [9]. R1 andR2 are reproduction numbers123
taking into account the restrictions f and fv, respectively. The R1S and R2SV are also group124
specific, but in addition incorporate the respective group sizes. Finally, R∗ combines all these125
factors together.126
Having this and Equation 5, we define the instantaneous doubling time at time, denoted t127
D(t), as the solution D of eγ(R∗(t)−1)·D = 2. Such obtained doubling times are featured in128
Figure 2b.129
8
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The times of transitions between subcritical and overcritical epidemics130
The analysis of the linearized dynamics around I = IV = 0 allows us to determine transitions
between subcritical and overcritical epidemics. Such transitions occur at the time instants t at
which λmax(t) = 0, or, equivalently, at R∗(t) = 1. We thus find that for given values of S(t)
and SV (t) the critical times t for transitions between subcritical and overcritical epidemics are
the roots of the equation
λmax(t) = 0.
The obtained critical threshold times are plotted in the lower triangles of the panels in Figure 3131
in the main text. In the case of proportional mixing the above equation is equivalent to:132
(R1S(t)− 1) (R2SV (t)− 1) = R21S(t)SV (t).
Asymptotic structure of the population133
The asymptotic structure of the population in terms of the sizes of the subpopulations V, SV134
and SD can be easily obtained by setting I = IV = R = RV = 0 and computing the stable135
stationary solution for V as, Sas and SasV of our ODE system (1):136
Sas = d
SasV = (1− d) (1− η)
V as = (1− d)η





can be seen as the actual immunization rate in the population, and is expressed as a function137
of vaccine effectiveness a and the ratio of the immunity waning rate ω and the revaccination138
rate υr. The obtained values correspond to the structure in the limit t → ∞ and represent the139
structure to which the population converges in the long term.140
9
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Having this, we obtain the asymptotic instantaneous reproduction number R∗ by inserting141
the asymptotic values Sas and SasV into Equation 8. These values are plotted in the upper142
triangles in the panels of Figure 3 in the main text.143
Finally, we solve for such minimum common restrictions f = fv = fmin, which will
result in instantaneous reproduction number R∗ = 1 for the different vaccine effectiveness









VAP-SIRS is not compartmentalized for age groups and does not consider deaths or healthcare145
system limitations like some other models, albeit in the context of exploring different parameters146
than larger freedom for VP holders [10, 11, 12, 13, 14, 15]. Deaths could be taken into147
account through a straightforward modification of the model, which would however lead to148
more parameters. In this case, the fact that vaccination reduces the risk of death would have to149
be accounted for. The impact of deaths on public health and society, which is very important150
especially when the epidemic becomes overcritical, can be indirectly assessed based on the151
number of infection cases. In general, features such as age groups and deaths, however, do not152
add further insights into the questions which are the focus of our study, namely, the long-term153
effects of VPs and avoiding overcritical dynamics. In this context, the advantage of our model is154
that it is enriched in features such as revaccinations and waning immunity, which are particularly155
relevant in the long term.156
Nevertheless, possible extensions to our model could include inter- individual or age-dependent157
variations in immunity, which is also relevant for people with severe chronic conditions or158
immunodeficiencies, or changes in behaviour over time. The presented analysis has been159
performed assuming that without restrictions, the maximum reproduction number of the virus160
is Rmax = 4. More transmittable variants could easily be modeled by fixing higher values of161
Rmax. Similarly, our results do not account for the possibility of immune escape variants, but162
such variants could be considered using our model by fixing smaller vaccine effectiveness than163
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the values we considered. Asymptotic endemic states of the ODE system (1) could easily be164
computed, but are not discussed here due to space constraints. Finally, another limitation of165
our analysis is that not all parameter values are exactly known, such as the post- vaccination166
or natural immunity waning time. We, however, fix optimistic values for such parameters, and167




The VAP-SIRS model was implemented using R version 4.0.2 along with the shiny package172
to build an interactive web application that allows to simulate the model. The code of the173
model is available online in the GitHub repository: https://github.com/storaged/174
VAP-SIRS, and the on-line tool is available http://bioputer.mimuw.edu.pl:85/175
VAP-SIRS/. The code to generate Fig 2 and Fig 3 from the main text is available at https:176
//github.com/eMaerthin/Fig2_Fig3.177
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